Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2003
03/13/2003WO2003020252A2 Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
03/13/2003WO2003020227A1 Compositions and methods relating to prevention of chemotherapy-induced alopecia
03/13/2003WO2003020217A2 Novel pyrazole analogs acting on cannabinoid receptors
03/13/2003WO2003020210A2 Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
03/13/2003WO2003020172A1 An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
03/13/2003WO2003020037A1 Multivesicular emulsion topical delivery systems
03/13/2003WO2003020005A2 Lp mammalian proteins; related reagents
03/13/2003WO2003000174A3 Compositions and methods for intracellular delivery
03/13/2003WO2002100354A3 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
03/13/2003WO2002099038A3 Adsls as modifiers of the p53 pathway and methods of use
03/13/2003WO2002098416A3 Antineoplastic combinations
03/13/2003WO2002097050A3 Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
03/13/2003WO2002096361A3 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
03/13/2003WO2002091997A3 Oncolytic virus therapy
03/13/2003WO2002088080A3 Dual inhibitors of pde 7 and pde 4
03/13/2003WO2002087513A3 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
03/13/2003WO2002077217A3 Human dual specificity protein phosphatase 7-like protein
03/13/2003WO2002076548A3 Methods and apparatus for treating diseased tissue
03/13/2003WO2002074291A3 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
03/13/2003WO2002072543A3 Rxr activating molecules
03/13/2003WO2002068388A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists
03/13/2003WO2002068015A3 Modular infusion device and method
03/13/2003WO2002065986A9 Transporters comprising spaced arginine moieties
03/13/2003WO2002053519A3 Hydrophobic polyamine analogs and methods for their use
03/13/2003WO2002050286A3 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
03/13/2003WO2002050102A3 Inhibitors of the e2f-1/cyclin interaction for cancer therapy
03/13/2003WO2002050019A3 Diamines as modulators of chemokine receptor activity
03/13/2003WO2002046459A3 Method for the determination of at least one functional polymorphism in the nucleotide sequence of a preselected candidate gene and its applications
03/13/2003WO2002046412A3 Regulation of angiogenesis with zinc finger proteins
03/13/2003WO2002046191A3 Urea substituted imidazoquinoline ethers
03/13/2003WO2002046188A3 Amido ether substituted imidazoquinolines
03/13/2003WO2002044379A3 Transforming growth factor-beta-related molecules and uses thereof
03/13/2003WO2002044364A3 Polypeptides involved in immune response
03/13/2003WO2002042456A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/13/2003WO2002042332A3 Truncated cd200
03/13/2003WO2002042319A3 2-substituted estrogens as antiangiogenic agents
03/13/2003WO2002039990A3 Method for screening anti-proliferative compounds and inhibiting tumor growth
03/13/2003WO2002038140A3 Therapeutic uses for ip3 receptor-mediated calcium channel modulators
03/13/2003WO2002036553A3 Substituted alkanoic acids
03/13/2003WO2002034708A3 Aliphatic amino-substituted demethoxylated hypocrellins and their synthesis
03/13/2003WO2002034293A3 Use of citric acid as antimicrobial agent or enhancer or as anticancer agent
03/13/2003WO2002031511A3 Modulation of ligand binding/enzymatic activity of alpha beta proteins
03/13/2003WO2002030986A3 HUMANIZED ANTI-LT-β-R ANTIBODIES
03/13/2003WO2002030465A3 Compositions that inhibit proliferation of cancer cells
03/13/2003WO2002026822A3 Pumpcn compositions and uses thereof
03/13/2003WO2002026802A3 M32404, a novel human trypsin and uses thereof
03/13/2003WO2002024179A3 Method for reducing toxicity of combined chemotherapies
03/13/2003WO2002024178A3 Method for reducing toxicity of combined chemotherapies
03/13/2003WO2002023190A3 Methods and products related to low molecular weight heparin
03/13/2003WO2002022686A3 Defensin-antigen fusion proteins
03/13/2003WO2002022151A3 Use of glp-1 and flp-2 peptides for treatment of bone disorders
03/13/2003WO2002020759A3 A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
03/13/2003WO2002020017A3 Use of ectoin or ectoin derivatives for stabilizing p53
03/13/2003WO2002013803A3 Chelerythrine-based therapies for cancer
03/13/2003WO2002012280A3 Compositions and methods for the therapy and diagnosis of colon cancer
03/13/2003WO2002012272A8 Therapeutic anti-melanoma compounds
03/13/2003WO2002011762A3 Methods and compositions for modulating tumor growth
03/13/2003WO2002008284A3 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
03/13/2003WO2002006340A3 Tetraspan protein and uses thereof
03/13/2003WO2002003957A3 Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
03/13/2003WO2002000690A3 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
03/13/2003WO2002000242A8 Human papilloma virus treatment
03/13/2003WO2001097848A3 Vitronectin receptor antagonist pharmaceuticals
03/13/2003WO2001096376A3 Pro-apoptotic fragments of the dengue virus envelope glycoproteins
03/13/2003WO2001082911A3 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
03/13/2003WO2001073032A3 Compositions and methods for the therapy and diagnosis of prostate cancer
03/13/2003US20030050620 Combinatorial type controlled release drug delivery device
03/13/2003US20030050495 4'-alkyl,6'-(protected hydroxy),7'-hydroxy-spiro(cyclopropane-1,5'-hexahydroindan-2,3 a(4),7a(1)-triene) compound of given formula, intermediate to illudin analogs of the mushroom Omphalotus illudens
03/13/2003US20030050466 Nucleotide sequences coding polypeptides for use in the diagnosis and treatment of cancer or autoimmune diaseses
03/13/2003US20030050461 Protein for use in the diagnosis, prevention and treatment of metabolic, developmental, nutrient transport and cell proliferation disorders
03/13/2003US20030050460 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cardiovascular and bone disorders
03/13/2003US20030050454 Oligonucleotide sfor use in the treatment of cancer and viral diseases
03/13/2003US20030050439 Polypeptide for use in the treatment of tumors and warts
03/13/2003US20030050345 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative
03/13/2003US20030050343 Novel potentiating compounds
03/13/2003US20030050333 Improved bioavailability; anticarcinogenic
03/13/2003US20030050331 Cytotoxic agents
03/13/2003US20030050325 Novel compounds of the indolecarboxylic family and use thereof
03/13/2003US20030050314 Treating bone disorder caused by osteoclasts, tumor growth and tumor metastasis, prophylaxis of cardiovascular disorders, nephropathies or retinopathies
03/13/2003US20030050310 Hydroxamic acid derivatives as proteinase inhibitors
03/13/2003US20030050299 An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents
03/13/2003US20030050298 A sulfonamide substituted diphenyl thiourea compounds treating a chemokine mediated disease
03/13/2003US20030050297 Administering to a mammal, a low molecular weight antioxidants, mimetics of superoxide dismutase
03/13/2003US20030050289 Combination of drospirenone and an estrogen sulphamate for HRT
03/13/2003US20030050279 Beta-glucans
03/13/2003US20030050272 Purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase nucleic acids and polypeptides
03/13/2003US20030050269 Polynucleotides and polypeptides of the erythropoietin gene
03/13/2003US20030050261 Immunostimulatory nucleic acid molecules
03/13/2003US20030050251 A polypeptide which inhibits or reduces tumor progression and/or metastasis
03/13/2003US20030050250 Administering an aromatic dipeptide derivative with a chemotherapeutic agent to treat tumor metastasis, solid tumor growth, angiogenesis and other neoplasia diseases
03/13/2003US20030050249 Complexes of alpha-6 integrin subunits with small peptides and methods for treating indications resulting from modulation of integrin-mediated responses by altering signal transduction
03/13/2003US20030050246 Peptides having antiangiogenic activity
03/13/2003US20030050245 A protein molecule that is a cofactor of tissue plasminogen activator and has a residue of lysine and/or arginine or an equivalent; angiogenesis inhibitors; antiinflammatory agents; antitumor agents; aging; degrads amyloid
03/13/2003US20030050242 Protein polymerization inhibitors and methods of use
03/13/2003US20030050235 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator
03/13/2003US20030050234 Conotoxin peptide extracted from the venom of a marine snail, Conus magnus (cono=cone); disorders associated with voltage gated sodium ion channel; neuromuscular blocking agents; local anesthetics; neuroprotective agents; analgesics
03/13/2003US20030050230 A nucleic acid encoding a family (title) of kinases from a group of sixteen polypeptides; identifying a substance that modulates kinase activity; autoimmune diseases; organ transplantation, cardiovascular disease, stroke, renal failure
03/13/2003US20030050224 Treatment of glial tumors with glutamate antagonists
03/13/2003US20030050222 Antineoplastic combinations
03/13/2003US20030049791 Goodpasture antigen binding protein
1 ... 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 ... 2211